## Are the Best Anatomic Total Shoulder Arthroplasties Better than the Best Reverse Total Shoulder Arthroplasties?

Jacob Kirsch<sup>1</sup>, Daniel Patrick Swanson, Kuhan A Mahendraraj, Ryan Lohre<sup>2</sup>, Christopher Fang<sup>3</sup>, Matthew Veale, Andrew Jawa

<sup>1</sup>Boston Sports and Shoulder Center, <sup>2</sup>University of British Columbia, <sup>3</sup>New England Baptist Hospital INTRODUCTION:

Surgeons often state anecdotally that their best anatomic shoulder arthroplasties (TSA) do better than their best reverse shoulder arthroplasties (RSA). Limited data exists comparing patients at the upper limits of outcomes between RSA and TSA.

## METHODS:

4 (3.1) 65 (50.8)

21 (16.4)

BMI; body mass index, ASA; American Society of Anesthesiologists' classification of Physical Health, VAS; Visu Analog Scale, SANE; Single Assessment Numeric Evaluation ASES; American Shoulder and Elbow Surgeons' Score r ouff tear, PCA; Post-c

Current Former

A retrospective study was performed in patients undergoing TSA and RSA with minimum two-year follow up. Baseline patient demographic information as well as preoperative and postoperative active range of motion (ROM), American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE), and Visual Analog Scale (VAS) for pain were collected. Patients in the top 20% of postoperative ASES scores were identified as the best outcomes. Descriptive statistics, univariate, and multivariate analyses were performed to evaluate differences between patients in the top 20% of ASES scores undergoing TSA and RSA.

RESULTS: A total of 40 TSAs and 88 RSAs were included in the top 20% of each group, from a total of 205 TSAs and 447 RSAs, with mean postoperative follow up of  $33 \pm 14$  months. Baseline patient-reported outcome measures (PROs) and ROM did not differ between groups (P > .05). There were no significant differences in the change of preoperative to postoperative VAS-pain (P = .539), SANE (P = .388), ASES (P = .912), and forward elevation (P = .439). The median (Interquartile range) change in external rotation ( $40^{\circ}$  ( $30^{\circ},50^{\circ}$ ) vs.  $30^{\circ}$  ( $20^{\circ},50^{\circ}$ ); P = .017) and internal rotation (4.0 (2.0,6.0) vs. 2.0 (1.0, 4.0); P = .005) was statistically different between the TSA and RSA groups, respectively. Minimal clinically important difference for ASES was achieved by 100% of patients in both groups. Substantial clinical benefit was achieved by 100% of patients in the TSA group and 98% (n = 86) of patients in the RSA group. DISCUSSION AND CONCLUSION:

While there is a common notion that patients treated with TSA have a greater potential for excellent outcomes, our findings show that clinical outcomes for the best TSAs are comparable to the best RSAs. Longer follow up is needed to identify long-term differences in outcomes including revision and implant durability.

dentify	long-ter	n differences				in	outcomes			including		revision						implan	
Table I. Whole Cohort Patien	at Demographic Information	Table II. Patient Demographic Is				Table III Industry of Astrophy	by Type on Clinical Outcomes TSA (g = 42)	85A (h=50)	P.Value	Table IV. Prosperative Factors Associat Factor	tel wik Top X OR -		CI	- P-Value	Table V. Preoperative Factors a Factor			Voper	- 7-Value
	n (%) or Average ± SD		TSA	RSA	P-Value	VAS-pain Score				Sex (referen male)	1.04	0.49	2.20	0.917	Sas (refearer male)	0.40	6.23	0.67	6.001*
		No. of patients	40	58	N/A	Pri-op Den-op	63 (43, 10) 8 (3,0) 68 (-10, -60)	8.0(4.0, 8.0) 0(8.0) 40148.440	0.500	Age	0.56	0.90	1.02	0.290	Apr	0.99	0.95	1.03	0.467
Total	128	Age (yr)	62.3±6.2	71.5±5.8	<0.001*	ANX Stars				ABA (reference: 2)	6.79	0.16	2.96	0.625	ASA (reference: 2)	1.08	0.20	5.86	0.926
Age (years)	68.6 ± 7.3	Mean clinical follow-up (mo)	40.4 ± 16.2	30.0 ± 11.1	<0.001*	Pro-op Pauloop	30.0 (20.8, 50.3) 100.0 (20.8, 30.3) 70.0 (30.8, 60.3)	12.5 (34.5, 50.0) 100.4 (94.4, 100.0) 52.5 (46.7, 10.5)	0.200	3	0.55	0.11	2.72	0.457	3	0.80	0.41	1.56	0.515
Sex		Sex (n (99))				ASES Some	409 (25.8, 49.5)	35.8 (27.6, 48.D		RM0 Dalates	6.99	0.83	0.98	0.022*	Bold Disbates	0.95	0.94	1.03	0.405
Female	63 (49.2)	Female Male	21 (53) 39 (47)	42 (48) 46 (52)	0.757	Drawp Pozrop A	100-0 (200.8, 200.8) 60-0 (20.4, 72-0)	100.8 (HL3, 100.0) 41.8 (SIL0, 71.7)	0.813	Sauking Status (reference netwi)					Smoking Status (reference: ner	er)			
Male	65 (50.8)	BMI	28.4 ± 3.7	30.1±6.3	0.051	54CED (4-(%)) 5CB (42%)	40 (200) 40 (200)	10 (310) 10 (90)	1.800	Previous Current	1.53 0.50	0.70	3.36 4.52	0.289 0.538	Former Ourseat	1.63 0.75	0.97	2.74 0.70	0.065 0.729
Follow-up (months)	33.2 ± 13.7	ASA comorbidity score [n(%)]				Ternard Elevation (Depter) Ternap	80(80,100)	90 (90, 130)		Point Surgery	6.24	0.05	0.70	0.009*	Prior Surgery Diamonis (reference: BCA)	0.37	6.39	0.71	6.033*
вмі	29.6 ± 5.7	1	3 (7.5) 35 (88)	2 (2.5) 69 (78)		Pos-op à	150(040,160) #C000,400	150 (135, 135) 10 (20, 40)	0.69	Assethedologists' classification of Physi	OE: Odds Entio, CI: Confidence Interval, ASA: American Society of Americanizingists' classification of Physical Health, ENE: Body Mass Index					1.00	0.54	1.89	0.979
	29.0 ± 3.7	3	2 (5)	17 (19)	0.033*	External Rotation (Degree) Fre-up	21 (26, 10)	30 (20, 30)		<ul> <li>Signifies significance with alpha nik.</li> </ul>	1et at 0.05				RCT Other	0.18 0.55	6.63 0.34	0.71 2.05	0.816* 0.375
ASA		Primary Diagnosis [n(%)]				Pee-op	70-00, 98	69 (59, 76) 19 (20, 90)	0.017*						OR; Odds Ratie, CI; Confidence classification of Physical Health				
1	5 (3.9)	GHOA	40 (100)	64 (72.7)		Internal Estation*									G290A; Gieschumenal Outscar	theis, NCT; 3	Retator Cuff Tear	; Kotator Cuff Art	repatie,
2	104 (81.3)	RCA	0	19 (21.6)	<0.001*	Pre-op	03(03,20) 69(25,63)	8.6 (8.6, 2.8) 4.6 (2.6, 4.0)							* Signifies significance with all	pha nisk set at	0.05		
3	19 (14.8)	RCT Other	0	2 (2.2) 3 (3.4)		Destrop 2	43(23,60)	2.6 (1.0, 4.0)	0.002*										
<b>Comorbid Conditions</b>		Prior Surgery (n(%)) 5 (12.5) 16 (19.2) 0.607			Account Nemeric Evaluation, 5	ASED: American Handler Ellow Inspace Store, SAND: Single Assessment Neuroic Evolution, VAI, Vand Analog Rods, IASED; Maintaly innovem Califord Alforence, SACE Substantial chained basefit													
Depression Diabetes	28 (21.9) 14 (10.9)	Complications [n(%)]	0	3 (3.4)	0.581	* Dearter Statistical Significance	nce, SCE; Substantial clinical benefit		_										
				0.0000		1 representing sectors. 2 represent	ng L5, and so on.												
Obesity Smoker	34 (26.6) 69 (53.9)		BMI; body mass index, N/A; not applicable, ASA; American Society of Americaneous classification of Physical Health																